| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
University of Iowa Cancer Center and Department of Internal Medicine, University of Iowa, Iowa City
Correspondence: George J. Weiner, Director, University of Iowa Cancer Center, C.E. Block Professor of Cancer Research and Internal Medicine, 5970Z JPP, 200 Hawkins Drive, University of Iowa, Iowa City, IA 52242. E-mail: george-weiner{at}uiowa.edu
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
Key Words: B cells • natural killer cells • antigen-presenting cells • allergic diseases • asthma
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
It was almost 100 years between Coley’s studies and the recognition that bacterial DNA itself can stimulate the immune system. Shimada, Yamamoto, and colleagues demonstrated that bacterial DNA could enhance natural killer (NK) cell activity [4 , 5 ], and Messina, Pisetsky, and colleagues found that such DNA was also capable of inducing B cell activation [6 ]. In the mid-1990s, Krieg and colleagues gained additional insight into the moieties in bacterial DNA that are responsible for the immunostimulatory effects of bacterial DNA. As with many pivotal discoveries, this one was serendipitous. While studying the effect of anti-sense DNA on B cell activation, these investigators found that a number of "control" oligodeoxynucleotides (ODN) also mediated B cell activation. After making and testing hundreds of ODN, it was determined that the immunostimulatory effects of these "control" ODN were dependent on an unmethylated CpG dinucleotide in a particular sequence context [7 ]. Specifically, the optimal stimulatory motif was determined to be as follows: R1R2CGY1Y2 where R1 is a purine (preference for G), R2 is a purine or T, and Y1 and Y2 are pyrimidines. Klinman et al. found these ODN not only induced B cell activation, but also induced production of a wide variety of cytokines, indicating a more complex pattern of immune activation [8 ].
Although teleological explanations are risky, it is fascinating to consider whether an immune response to unmethylated CpG motifs enables the mammalian immune system to distinguish microbial DNA from self DNA. Indeed, it is easy to conceive how having bacterial DNA serve as a "danger signal" would be advantageous. Sequence differences between bacterial DNA and vertebrate DNA appear to make this possible. CpG dinucleotides are present at the expected frequency in bacterial DNA (1 in every 16 dinucleotides) while mammals have CG suppression, with CG dinucleotides being found at approximately one-fourth the expected frequency [9 ]. Furthermore, the majority of cytosines present in CG dinucleotides are methylated in mammals. Although bacteria can methylate select bases, there is no methylation specificity for CG dinucleotides. Thus, unmethylated CG dinucleotides are much more common in bacteria than in mammals and other vertebrates.
We now know that the immunostimulatory effects of specific motifs within bacterial DNA, including CG dinucleotides, likely play an important role in the immunostimulatory effects of various bacterial preparations that have been observed over the years. Attenuated mycobacteria are currently used for treatment of superficial carcinoma of the bladder [10 ]. Yamamoto et al. found that mycobacterial DNA could result in tumor regression, and that this was accompanied by induction of interferon secretion, and NK lytic activity [11 ]. In further studies, these investigators found that DNA from a variety of bacteria could cause interferon (IFN) secretion and tumor regression, whereas vertebrate DNA did not [5 ].
Over the past 5 years there has been a dramatic increase in our understanding of the molecular and cellular effects of CpG DNA, and its effects in vivo in animal models. Studies to date suggest CpG DNA could have significant therapeutic promise in the treatment of a variety of disorders, including infectious disease, allergy, and cancer. Despite these rapid advances, there is still much we have to learn about these potent immunostimulatory agents. Clinical trials in these areas have only recently begun. In this review, we will outline what is known (and what is not known) about CpG DNA at the molecular, cellular, and intact animal level, and will discuss the potential for clinical utilization of this novel class of compounds (see Table 1 for summary).
|
|
MOLECULAR EFFECTS OF CPG ODN |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
Whether or not a specific surface receptor is involved, uptake of CpG ODN is saturable and both energy and temperature dependent [14 ]. As is the case for other ODN [15 ], CpG ODN appear to be taken up in a nonspecific manner through acidic vesicles in the endosomal compartment. Drugs that interfere with endosomal acidification, such as quinacrine, inhibit the immunostimulatory activity of CpG ODN [14 , 16 ].
Transcriptional activation induced by CpG ODN is very rapid, and is detectable within 15 min [17 , 18 ]. Although there are hints that CpG ODN binds specifically to select proteins in both the cytoplasm and nucleus, the identity of CpG binding proteins has yet to be determined. Description of such proteins will be of obvious importance as we work to understand the molecular mechanisms responsible for the immunostimulatory effects of CpG ODN. Given the importance of CG methylation in transcriptional control, an area of intense interest is how CpG ODN might interact with transcription factor complexes. Indeed, the complexity of these structures may account for the difficulty encountered to date in identifying the CpG receptor.
What we do know is that generation of intracellular reactive oxygen
species (ROS) occurs within minutes of exposure of cells to CpG ODN,
and is associated specifically with CpG ODN and not with non-CpG ODN
[17
, 18
]. Multiple downstream changes then
occur, including nuclear factor-
B (NF-B) activation
[19
]. Indeed, activation of NF-B by ODN was noted
before the immunostimulatory effects of CpG ODN were described
[20
]. Changes that follow NF-B activation include
production of tumor necrosis factor (TNF) and interleukin (IL)-1
ß
[19
]. CpG ODN can also impact on additional signaling
pathways, and can induce changes such as activation of
mitogen-activated protein kinases (MAPKs) and stress kinases such as
JNKK1 [14
, 18
].
Investigation into the interaction of CpG ODN with cytokine gene promoters is supplying further evidence for the molecular complexity of the mechanisms responsible for the immunological effects of CpG ODN. Takeshita et al. have used site-directed mutagenesis of the IL-6 promoter to demonstrate CpG ODN regulation of IL-6 gene expression involves both enhancer and derepression mechanisms [21 ]. More detailed descriptions of signaling and CpG ODN have recently been published [22 , 23 ]. Our knowledge with respect to the specifics of CpG ODN-mediated signaling is sure to expand rapidly in the near future given the number of excellent investigators currently working in this area.
|
CELLULAR EFFECTS OF CPG ODN |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
CpG ODN can also activate antigen-presenting cells (APCs) including
monocytes, macrophages, and dendritic cells [27
]. This
plays a central role in the overall immune response to CpG ODN. Effects
of CpG ODN include induction of cytokine production and change in
phenotype. Production of a growing number of cytokines is increased by
CpG ODN including IL-6, IL-12, IFN-
, IFN-ß, TNF-, IL-1ß, and
IL-18 [8
, 28
, 29
]. Phenotypic
changes on professional APCs are similar to those seen with B cells,
and include induction of MHC and costimulatory molecule expression.
Actual changes vary with different CpG ODN and from cell type to cell
type, however, a common theme is that CpG ODN induce maturation of
immature APCs. For example, dendritic cells derived from both bone
marrow and skin up-regulate class I, class II, CD80, CD86, and CD40,
and produce IL-12 [30
31
32
].
NK activity is also increased by CpG ODN [33
]. Much of
this effect is indirect because highly purified NK cells are not
strongly activated by CpG. IL-12 and IL-18 likely play a key role in
this response. There appears to be a positive feedback loop between
APCs and NK cells [34
]. NK cells secrete IFN- after
being stimulated by IL-12 and IL-18 that is produced by CpG
ODN-stimulated APCs. This IFN- further activates the APCs.
The effects of CpG ODN on T cells remains controversial. Clearly, the activation of APCs by CpG ODN has potent, if indirect, effects on T cells [35 ]. Some investigators have reported that CpG ODN also has direct effects on T cells, and can supply a costimulatory signal directly to the T cell [36 , 37 ]. We have been unable to detect such an effect. Because different sets of ODN were used by these two groups, it is possible the costimulatory effect on T cells was due to non-CpG motifs in the ODN, and not to the CpG motif itself. Further work is needed in this area. Nevertheless, this points out the complexity of the responses to immunostimulatory DNA.
|
IN VIVO EFFECTS OF CPG ODN |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
[8
, 40
]. IL-6 and IL-12
secretion is increased within 4 h after in vivo
treatment with CpG ODN. CpG ODN is, in general, well tolerated whether
CpG ODN is given intravenously, subcutaneously, or intraperitoneally
with no formation of sterile abscesses as is seen with complete
Freund’s adjuvant. Toxicity can be seen in select conditions. Repeated large doses of CpG ODN can cause a wasting syndrome, and ultimately can be fatal to mice, apparently due to massive B cell proliferation and cytokine production. Toxicity has also been observed with the combination of CpG ODN and lipopolysaccharide (LPS), with CpG effectively priming mice for a Schwartman-like reaction when a small dose of LPS is given a few hours after CpG ODN [40 ]. As clinical trials progress, particular caution will need to be taken when CpG ODN are combined with other agents that induce activation of monocytes and macrophages. It will also be important to monitor whether CpG ODN therapy increases the toxic systemic effects of bacterial infection.
|
HETEROGENEITY OF CPG ODN EFFECTS |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
In addition, the anti-sense literature teaches us that the phosphorothioate backbone of ODN has non-sequence-specific immunostimulatory effects. For example, non-CpG phosphorothioate ODN have been shown to activate the transcription factor Sp1, which plays a key role in translation of multiple genes [43 ]. It is important to note that stimulatory effects of non-CpG phosphorothioate ODN are relatively limited when compared to the effects of phosphorothioate CpG ODN.
A variety of cell populations are activated by CpG ODN, and CpG ODN
with different sequences vary in their ability to activate various cell
populations. There is also variability from species to species
[44
]. This makes definition of the immunological effects
of a specific CpG ODN complex. Despite this heterogeneity, a number of
patterns of cellular activation appear to be emerging, which is
allowing us to designate various classes of CpG ODN. Some CpG ODN
induce significant activation of APCs (monocytes, dendritic cells), NK
cells, and production of IFN-, but have little impact on B cells.
This class of ODN has recently been designated as "CpG-." Other
CpG ODN activate APCs and NK cells, but induce little IFN-. These
CpG ODN are potent activators of B cells. These are designated
"CpG-ß." The rules related to which CpG ODN will be CpG- and
which will be CpG-ß are only now being worked out. What is clear is
that the CpG motifs are not the only sequences that are relevant and
that the nucleotides preceding and following the CpG motifs can have a
significant impact on the immune effects of the ODN [33
,
41
, 45
, 46
].
|
CPG ODN TO ENHANCE INNATE IMMUNITY AND AS AN IMMUNE ADJUVANT FOR IMMUNIZATION |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
The ability of CpG ODN to enhance the innate immune system, as indicated by activation of NK cells and monocytes, could be of use in itself. CpG ODN is a highly effective therapeutic agent for the treatment of murine models of leishmania [43 ] and is also protective against a challenge with Listeria monocytogenes [47 ]. CpG ODN is currently being investigated for its ability to enhance innate immune defenses against other infectious organisms.
In addition to enhancing innate immunity, CpG ODN may be useful in preventing and treating infectious diseases based on its ability to enhance an antigen-specific response. CpG ODN is also attractive as a component of cancer vaccine strategies. Immune adjuvants used most extensively today enhance the Th2 response, and do not markedly enhance cellular immunity. Aluminum hydroxide is used in most commercial vaccine preparations and has been shown to actually block activation of CD8+ cytotoxic T lymphocytes (CTLs) in mice [48 ]. Other adjuvants that induce an enhanced Th1 response are currently being evaluated in both pre-clinical and clinical studies [49 ]. These include threonyl-muryl dipeptide [50 ], a variety of attenuated or killed bacteria [51 ] and bacterial derivatives [52 ], BCG [53 ] and Quillaja saponaria 21(QS21) [48 ], which has shown promise in preliminary clinical trials. However, none of these adjuvants are ideal due to toxicity (including both systemic toxicity and local inflammation after repeated immunization), limited efficacy at stimulating a cellular response, or difficulties associated with production.
A variety of characteristics of CpG ODN make them attractive as immune
adjuvants. CpG ODN is inexpensive to produce. As reviewed above, there
is significant synergy between signals delivered through the B cell
receptor and CpG ODN that results in enhanced production of antibody.
CpG ODN also has potent effects on APCs and enhances their ability to
present antigen. Studies in a range of animal models have demonstrated
that CpG ODN can serve well in this capacity. Using hen-egg lysozyme
(HEL) as the antigen, Chu et al. found that immunization in incomplete
Freund’s adjuvant (IFA) resulted in Th2-dominated immune response
characterized by HEL-specific secretion of Th2 cytokines (i.e., IL-5
but not IFN-). In contrast, immunization with HEL and CpG ODN
switched the immune response to a Th1-dominated cytokine pattern (high
levels of IFN- and decreased IL-5) [39
,
54
]. CpG ODN also enhanced production of anti-HEL IgG2a
when compared with IFA-HEL. This Th1 response was more marked than that
seen with complete Freund’s adjuvant (CFA) despite a lack of local
inflammation with CpG ODN. Davis and colleagues also found that CpG ODN
markedly increased antigen-specific IgG and particularly IgG2a, using
hepatitis virus B surface antigen as the immunogen [55
].
It is important to note that they also found that CpG ODN enhanced
development of a hepatitis virus B surface antigen-specific cytotoxic T
cell response. Lipford et al. found a similar humoral and cellular
response using ovalbumin as the target antigen [56
].
Results with models of influenza are also promising, and have
demonstrated that CpG ODN can enhance immunization delivered via the
mucosa [57
].
Our studies in a tumor model utilized the Id from the 38C13 murine lymphoma model as the target antigen. CpG ODN was as effective as CFA at inducing an antigen-specific antibody response, and was associated with less toxicity [42 ]. Again, CpG ODN induced a higher titer of antigen-specific IgG2a than did CFA. Therapeutically, mice immunized with CpG ODN as an adjuvant and Id-KLH as the immunogen were protected from tumor challenge to a degree similar to that seen in mice immunized with CFA and Id-KLH but with less toxicity [42 ]. In addition, there was synergy between CpG ODN and granulocyte-monocyte colony-stimulating factor (GM-CSF) [31 ].
Studies in primates are also promising. Davis et al. have found that CpG ODN can markedly enhance the response of orangutans to hepatitis B immunization. A significant fraction of orangutans are hyporesponsive to current commercial hepatitis B vaccines. The addition of CpG ODN to the vaccine markedly increased the seroconversion rates and greatly enhanced the antibody response [58 ]. After two doses, 100% of animals immunized with CpG ODN plus the vaccine had protective levels of antibodies compared to only 8% of animals immunized with the commercial vaccine.
Most importantly, similar results have recently been reported in the first human trial with CpG ODN. Two weeks after the first immunization of normal volunteers, 92% of subjects receiving CpG ODN combined with vaccine had antibodies compared to 0% of the subjects receiving vaccine alone. Two and four weeks after the second dose, antibody titers were more than 30 times higher in subjects receiving CpG ODN plus vaccine when compared to vaccine alone (Arthur Krieg, personal communication).
Data in both the murine and human systems demonstrate that CpG ODN can enhance T cell activity by activating APCs and improving their ability to present antigen and activate T cells. This concept fits well with the recent focus of adoptive immunotherapy studies on therapy with ex vivo activation of APCs. Studies evaluating the immune effects of dendritic cells (DCs), which are extremely potent APCs, are particularly promising [59 , 60 ], particularly given their ability to induce a cellular immune response [61 , 62 63 64 ]. Levy and colleagues have demonstrated induction of an antigen-specific cellular response after treatment with antigen-pulsed DCs in a small clinical trial [65 ]. This was in stark contrast to the studies, reported by the same group, which demonstrated that immunization of patients with Id-KLH leads to an intense humoral response [66 ]. Enhanced immune activation in patients immunized with DCs pulsed with melanoma-associated antigens has also been reported recently [67 ].
Studies exploring the effect of CpG ODN on DCs have only recently
begun. These preliminary investigations indicate CpG ODN can enhance
the ability of some subpopulations of DCs to present antigen and induce
an antigen-specific cellular response. Sparwasser et al. have shown
that CpG ODN induces maturation of immature DC obtained from murine
bone marrow and activates mature DC to produce cytokines, including
IL-12, IL-6, and TNF- [32
]. Jakob et al. found that
treatment of DCs derived from murine fetal skin decreased
E-cadherin-mediated adhesion, up-regulated MHC class-II and
co-stimulatory molecules, and enhanced accessory cell activity.
Injection of CpG ODN into murine dermis led to enhanced expression of
MHC class II and CD86 by the Langerhans cells [30
]. We
also found that CpG ODN markedly enhance the production of cytokines,
including IL-12, from DCs derived from murine bone marrow through the
use of GM-CSF and IL-4 [31
], and that CpG ODN can
enhance the survival, maturation, and differentiation of primary human
DCs isolated from the peripheral blood [45
]. Clearly,
DCs do not represent a single population of cells. The ideal source of
DCs or approach to in vitro expansion, activation, exposure
to antigen, and re-infusion has yet to be determined. Nevertheless,
there is reason to believe CpG ODN could be useful in enhancing the
immunological response to DCs.
Another area of intense interest in the field of immunotherapy is the
use of immunization using DNA constructs containing sequences that code
for the antigen of interest [68
69
70
]. The intent of such
therapy is to have host cells take up the DNA, produce protein coded by
the DNA, and express peptides derived from that protein in host class I
MHC, thereby inducing a cellular immune response directed toward that
antigen. It remains unclear whether these functions can be performed by
any cells (such as myocytes) that take up the DNA, or whether
professional APCs are required [71
, 72
].
Nevertheless, the inclusion of sequences containing the CpG motif as
part of the construct seems to enhance the resulting immune response in
animal models. Sato et al. found that human monocytes transfected with
plasmid DNA or double-stranded oligonucleotides containing CpG
sequences transcribed larger amounts of IFN-, IFN-ß, and IL-12
when compared with cells transfected with DNA that did not contain such
sequences [73
]. Thus, modifying the CpG content of
vectors intended for DNA immunization can have a significant impact on
their ability to induce development of a cellular response
[74
]. The ability to construct vectors that encode for a
specific protein and enhance a Th1 response to peptides derived from
that protein would have clear implications in the area of vaccination
for intracellular parasites and cancer and is currently undergoing
intense investigation.
|
CPG ODN AS A TREATMENT FOR ALLERGY AND ASTHMA |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
Kline et al. have used an inhalation mouse model to demonstrate that
systemic CpG ODN can prevent the development of airway eosinophilia and
bronchial hyperreactivity in animals sensitized to an allergen
(schistosome eggs) [76
]. This therapeutic response is
associated with a decrease in IL-4, and an increase in IFN- and
IL-12 in the airway fluid. An area of some controversy relates to
whether conjugation of the allergen to the ODN is required to obtain an
optimal therapeutic response. Raz and colleagues have performed a
series of studies suggesting this is the case. The most convincing of
these studies involved conjugation of a ragweed allergen to
CpG-containing immunostimulatory DNA sequences (termed "ISS"). This
conjugate suppressed the IgE response in a number of species
[77
].
As outlined above, one effect of CpG ODN is to drive immature APCs toward induction of a Th1-type response. Thus, the activation of APCs and B cells raises the possibility that treatment with CpG ODN could lead to the induction of autoantibody production and other forms of autoimmunity [78 ]. Animal models are mixed in this regard, with some failing to demonstrate induction or exaggeration of autoimmunity [79 , 80 ], whereas others suggest ODN could enhance the severity of disease in model systems of autoimmunity [81 ]. Further work is clearly needed in this area.
|
CPG ODN AS A CANCER THERAPY |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
, IL-12, and IFN- [29
, 33
,
40
]. These cytokines are now available in recombinant
form, and are known to have anti-tumor effects in both animal models
and clinical trials [82
83
84
]. Unfortunately, clinical
responses to these cytokines have, in general, been limited, and
significant toxicity has been noted. The immune response normally
involves the integrated production of a variety of cytokines that work
in concert both locally and systemically. It is rational to hypothesize
that CpG ODN, which is able to orchestrate the production of cytokines
by the host both temporally and spatially, could be more effective and
less toxic than recombinant cytokines at inducing an anti-tumor
response. In addition to stimulating cytokine production, CpG ODN have
direct effects on immune cell subpopulations that play an important
role in anti-tumor immunity, including NK cells [33
], B
cells [7
], monocytes and macrophages [32
,
85
], and dendritic cells [30
,
31
, 45
]. In vivo, systemic administration of CpG ODN as a single agent can have anti-tumor effects that appear to be related to enhanced NK activity. Smith et al. used a murine model of lymphoma to evaluate the anti-tumor effects of an antisense phosphorothioate DNA designed to block the c-myc oncogene. Both antisense DNA and control sequences inhibited tumor growth. Further investigation demonstrated that the immunostimulatory effect of the DNA, and not anti-sense activity, was responsible for the observed anti-tumor effects [86 ]. Carpentier et al. have demonstrated that CpG ODN can induce in vivo rejection of neuroblastoma xenografts, most likely due to activation of NK cells [87 ]. We have found that CpG ODN inhibits the in vivo growth of B16 melanoma cells and EL4 lymphoma in both immunocompetent and severe combined immunodeficiency mice that lack T or B cells but retain NK function. Removing NK cells eliminated the anti-tumor response [unpublished results]. Although toxicity from CpG ODN in these and other animal models has been limited, toxicity from nonspecific anti-cancer therapy often limits clinical efficacy. Clinical trials currently underway will help us determine whether CpG ODN used to stimulate the innate immune system have promise in the treatment of cancer.
Enhancement of the innate immune system can be used to increase anti-tumor activity in a more specific manner if used in combination with passive administration of agents that allow for tumor targeting, such as monoclonal antibodies. Recent clinical studies demonstrate unlabeled monoclonal antibodies as single agents have significant anti-tumor activity in a number of tumor types, including lymphoma and breast carcinoma [88 , 89 ]. Despite this success, there continues to be significant room for improvement, with most patients responding only transiently. Antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells and monocytes/macrophages likely plays a large role in the observed clinical responses. The addition of CpG ODN to activate NK cells and monocytes/macrophages, could therefore enhance the efficacy of antibody therapy.
Indeed, we found that CpG ODN-activated murine splenocytes or human peripheral blood lymphocytes mediate ADCC more effectively than do unactivated lymphocytes. In vivo, CpG ODN alone had no effect on survival of mice inoculated with the 38C13 murine B cell lymphoma. However, a single injection of CpG ODN enhanced the anti-tumor response to anti-tumor antibody therapy [90 ]. The combination of antibody plus a single dose of CpG ODN was more effective than antibody with multiple doses of IL-2 at inhibiting tumor growth. More recently, we have found that repeated doses of antibody plus CpG ODN can eliminate tumor load estimated to be 30-fold greater than can antibody alone [unpublished results]. Thus, use of CpG ODN to enhance the efficacy of antibody therapy remains promising. A clinical trial designed to assess this possibility will begin shortly.
Although vaccination for infectious diseases has had a major impact on worldwide public health, development of cancer vaccines has been more difficult. Most challenging in the development of cancer vaccines is the need to break immune tolerance against an antigen, and induce a tumor-specific immune response, including a cellular response strong enough to induce tumor cell destruction [64 , 91 , 92 ]. According to classic immunological teaching, intracellular proteins are processed and presented in class I molecules, and this leads to a cellular immune response. In contrast, extracellular antigens are taken into the cell and presented in class II molecules, which leads to a humoral response. It is now accepted that there is cross-talk between the class I and class II pathways, with some extracellular antigens taken up by APCs and processed in a manner that leads to presentation in class I molecules and development of a CTL response [93 ]. There is now evidence in a number of systems that CpG ODN enhances "cross-priming." In these systems, APCs process exogenous antigen and present peptides derived from such antigens in class I MHC. CpG ODN enhances this effect so that an effective cellular response can be induced by immunization with an intact model antigen [56 ]. Clinical trials will be needed to determine whether such a response can be elicited in humans.
There is also growing evidence that CpG ODN can impact on cells that are not strictly considered part of the immune system. CpG ODN induces mobilization of hematopoietic cells and extramedullary hematopoeisis, particularly in the spleen [38 ]. Ongoing studies are exploring the effect of CpG ODN on marrow reconstitution after a variety of myelosuppressive treatments. Whether similar effects on hematopoeisis will occur in humans remains to be seen.
|
CONCLUSIONS |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMOLECULAR EFFECTS OF CPG...CELLULAR EFFECTS OF CPG...IN VIVO EFFECTS OF...HETEROGENEITY OF CPG ODN...CPG ODN TO ENHANCE...CPG ODN AS A...CPG ODN AS A...CONCLUSIONSREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  G. Oganesyan, S. K. Saha, E. M. Pietras, B. Guo, A. K. Miyahira, B. Zarnegar, and G. Cheng IRF3-dependent Type I Interferon Response in B Cells Regulates CpG-mediated Antibody Production J. Biol. Chem., January 11, 2008; 283(2): 802 - 808. [Abstract] [Full Text] [PDF]
|
|
